ANX: Why i like it for the longer term?
The volume is unlike other similarly priced biotech stocks. Volume has been picking up huge the last couple of weeks. There appears to be lots of hope with this one. Phase III application has been filed for both U.S. and Europe/UK.
Their Co-Factor agent is a non-competing product to those of other biotech/pharmaceutical companies, imo. What i mean is that they are not creating, say, a new cancer drug or a Parkinson's drug, etc. If they were to do that, the new drug would have to be as effective to another company's drug. What's the chance of doing that for a small company such as this? Mr. Big Money Pharma ain't gonna like it! lol....... Instead, what they are doing is to create a "co-factor" that works in concert with the currently available cancer drug(s) in the market, to improve the efficacy of those drugs.
I like ANX alot. Once the FDA approves the Phase III trials, we should get a humongous gap up when the news hits the fan. And another huge gap up when European agency approves it. We have a double-whopper waiting in the wings. How's that for a hungry long?
I highly urge everyone to put ANX on your radar. I believe we are at the groundfloor of an emerging company.
Their Co-Factor agent is a non-competing product to those of other biotech/pharmaceutical companies, imo. What i mean is that they are not creating, say, a new cancer drug or a Parkinson's drug, etc. If they were to do that, the new drug would have to be as effective to another company's drug. What's the chance of doing that for a small company such as this? Mr. Big Money Pharma ain't gonna like it! lol....... Instead, what they are doing is to create a "co-factor" that works in concert with the currently available cancer drug(s) in the market, to improve the efficacy of those drugs.
I like ANX alot. Once the FDA approves the Phase III trials, we should get a humongous gap up when the news hits the fan. And another huge gap up when European agency approves it. We have a double-whopper waiting in the wings. How's that for a hungry long?
I highly urge everyone to put ANX on your radar. I believe we are at the groundfloor of an emerging company.
posted by beanie11111 | 12:47 AM
8 Comments:
Hey people, it is not the time to take profits on ANX. We are headed higher. The bottom of 2.40 held extremely well.
Take that, ANX shorties!!!! You might as well have someone bend ya over and kick ya out the winda! lol
NEOM is gonna fly as well!
Holy cow! The market is taking a beating and both of our picks are flying.
I am putting a 3-month target of $10 on ANX. We should get some data points regarding the studies this quarter.
The truth is, i find the volume increase in the last 2 months rather significant. The truth, i believe, will reveal itself in the next few months.
Some products being developed by ANX:
CoFactor
CoFactor is a folate-based chemotherapy drug designed for use with 5-FU, a frequently used cancer drug. Clinical data in previous clinical trials in Europe have demonstrated that CoFactor can block cancer cell growth by creating more stable binding of the target enzyme TS. CoFactor's potential indications include metastic GI and breast cancers, metastic colorectal cancer and metastic pancreatic cancer.
BlockAide/CR
BlockAide/CR is a peptide-based drug that is representative of the new "fourth modality" of HIV therapeutics that is intended to work by blocking viral entry and infection of human immune system cells. In non-human primate studies, BlockAide/CR demonstrated the ability to reduce viral load by nearly 100 fold in only two weeks of daily treatments. This compound also inhibits syncytia formation that causes the progression of AIDS. The Company is the exclusive licensee of this compound.
Thiovir
Thiovir, and other Thiovir-analogues under development, are parts of a new class of compounds known as thiophosphonoformates, which have demonstrated powerful antiviral properties. Thiovir is an oral replacement for the IV-administered antiviral drug, foscarnet, which is United States Food and Drug Administration (FDA)-approved for treatment of cytomegalovirus (CMV) infection in HIV patients. Clinical observations of patients treated with Thiovir have documented the broad-spectrum efficacy of this drug, which includes inhibition of HIV and HSV (herpes simplex virus) and the hyper sensitization of previously AZT resistant patients to AZT therapy. The Company is the exclusive licensee of this compound.
EradicaAide
EradicAide vaccine technology is based upon a cell-mediated immunity approach to controlling HIV, by stimulating disease-fighting cells, called killer-T cells (cytotoxic T cells) whose function it is to clear infection. Merck's DNA vaccine, now in human trials, demonstrated the ability to stimulate killer-T cells in some patients, indicating that this is a viable approach, but needs to be improved significantly to achieve more universal results. The Company is the exclusive licensee of this compound.
EradicAide is a therapeutic vaccine with a formulation that does not stimulate the production of antibodies, which have been shown to enhance HIV infection in studies designed to observe how HIV spreads. Antibody-based vaccines have achieved only mixed results in human testing, such as the poor results reported by VaxGen in February 2003, which caused VaxGen to discontinue this effort in early 2004.
Feasibility of the EradicAide vaccine approach has been demonstrated in multiple primate studies where rhesus monkeys, after a single series of vaccinations, have been infected with SHIV virus and have been able to keep infection under control for up to three years. This may translate to superior results in human trials, since the Company's animal testing has been both successful and extensive compared to animal testing of DNA vaccines that have been reported in the literature.
BlockAide/VP
BlockAide/VP is an HIV viral entry inhibitor that mimics a section of the CD4 receptor on human immune system cells. When BlockAide/VP comes into contact with the gp120 protein present on the surface of HIV, it appears to cause a change in the protein-folding configuration of gp120, rendering the gp120 unable to initiate the infection process that requires it to bind to the CD4 receptor. Early in-vitro tests indicate that HIV virus exposed to human immune system cells, with the BlockAide/VP compound present, are unable to bind to and infect such cells. During 2004, ADVENTRX intends to complete preclinical development and assessment of this drug during to determine whether to move forward into clinical development in 2005 and beyond. The Company is the exclusive licensee of this compound.
Selone
Selone is a compound in a new class of drugs known as organoselenones, consisting of carbon, oxygen and selenium. Selone and its analogues are effective, at even relatively low concentrations, against human ovarian, breast and lung and head/neck cancers, as well as against leukemias and lymphomas, based upon current in-vitro screening methods. Organoselenones' potency is high for their rate of alkylating activity, suggesting an increased specificity of action. Preclinical efforts have demonstrated effectiveness of Selone in treatment of leukemia in mice, at doses predicted to easily achieve effective blood concentrations, and in a variety of human tumor cell lines in laboratory testing. The Company intends to undertake further preclinical testing of Selone, during 2004 and into 2005, in order to determine the potential for this drug to be moved into human testing in the future. The Company is the exclusive licensee of this compound.
Let's take 1/2 off NEOM on Monday and ride the rest long term essentially for free.
Post a Comment
<< Home